As of January 2021, two immune checkpoint inhibitors have been approved by the FDA for breast cancer: (1) atezolizumab (PD-L1 inhibitor) with protein-bound paclitaxel for locally advanced, non-removable TNBC or metastatic TNBCs that are PD-L1 positive (IMpassion130 trial) [43], and (2) pembrolizumab (PD-1 inhibitor) for locally recurrent unresectable or metastatic TNBCs that are PD-L1 positive (KEYNOTE-355) [44]. Here, CD274 is linked to breast cancer.